$BLFS. breakout candle held: $2.10 Above upper bo
Post# of 44
(Total Views: 654)
Posted On: 02/14/2017 7:24:37 AM
$BLFS. breakout candle held: $2.10
Above upper bollie
Nasdaq CM
Ultra Low Float (below)
Website
2/14/17
$BLFS an equity partner in SAVSU Technologies
SAVSU Technologies Provides Performance Update
on evo® Cold Chain 2.0™ System in ImmunoCellular Therapeutics
Phase 3 Glioblastoma Cell Therapy Clinical Trial
Website
BioLife Solutions Announces 2016 Revenue Growth of 28 %
2017 Guidance Provided 1/12/17
100% x 100% Strong Buy
10 K/A 12/9/2016
Last 10 trades
Stock technical analysis
Shares Outstanding 12.88M
Float 6.3M
% Held by Insiders 51.44%
% Held by Institutions 3.40%
Shares Short 199.37k
Short Ratio 5.8
Short % of Float 6.04%
Shares Short (prior month) 208.77k
The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services.
Above upper bollie
Nasdaq CM
Ultra Low Float (below)
Website
2/14/17
$BLFS an equity partner in SAVSU Technologies
SAVSU Technologies Provides Performance Update
on evo® Cold Chain 2.0™ System in ImmunoCellular Therapeutics
Phase 3 Glioblastoma Cell Therapy Clinical Trial
Website
BioLife Solutions Announces 2016 Revenue Growth of 28 %
2017 Guidance Provided 1/12/17
100% x 100% Strong Buy
10 K/A 12/9/2016
Last 10 trades
Stock technical analysis
Shares Outstanding 12.88M
Float 6.3M
% Held by Insiders 51.44%
% Held by Institutions 3.40%
Shares Short 199.37k
Short Ratio 5.8
Short % of Float 6.04%
Shares Short (prior month) 208.77k
The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services.
(0)
(0)Biolife Solutions Inc. (BLFS) Stock Research Links
Scroll down for more posts ▼